Why is Veracyte stock plummeting today?
Veracyte (VCYT) fell 31% pre-market to $36.25 after Q3 2026 earnings. Revenue grew 15% YoY to $151.8M, beating EPS estimates, but guidance was cut. Decipher Prostate test missed targets. Analysts downgraded, citing reduced growth expectations. NASDAQ declined 0.6%, amplifying the drop.
How this was made
The 30-second read
Why it matters
Guidance downgrade triggered a sharp pre‑market sell‑off, highlighting sensitivity to growth outlook in high‑beta biotech stocks.
Market read
The news is highly relevant for traders with exposure to biotech and high‑beta stocks, less so for broader market participants.
What to watch
Potential upside from Afirma test performance and possible future partnership announcements.
Background
Veracyte is a US‑listed molecular diagnostics company; its Decipher Prostate test is its flagship product.
Ticker impact
Veracyte reported Q3 2026 earnings with revenue beat but sharply lowered 2026-2027 guidance, causing a 31% pre‑market plunge.
likely continued downward pressure as investors price in slower growth
The guidance reduction is a fresh, material change that directly drove the pre‑market drop; no offsetting positive news was presented.
Market effects
May weigh on other genomic‑testing and precision‑medicine stocks.
Limited to US biotech sector; broader market largely unchanged.
Low; impact confined to investors tracking US biotech earnings.
Counterpoint
Some traders may view the earnings beat as a buying opportunity if the guidance cut is seen as temporary.
Key entities
- companyVeracyte
Molecular diagnostics firm (ticker VCYT).
- analystLeerink Partners
Downgraded Veracyte to Market Perform with $35 target.
- analystNeedham
Reduced price target to $46.
